Abstract: A recombinant herpesvirus (excluding infectious laryngotracheitis virus) having a DNA that encodes a polypeptide comprising 429 amino acids at the amino terminal end of a protein encoded by the gB gene of infectious laryngotracheitis virus or a polypeptide in which one or a plurality of amino acids have been deleted, added, or substituted in said polypeptide.

Abstract: The present invention provides a recombinant herpesvirus of turkeys modified by the presence of cDNA encoding the F protein of Newcastle disease virus under the control of a promoter. The poultry vaccine consisting of the recombinant herpesvirus of turkeys of the present invention can induce in chickens protective immunity against Newcastle disease virus.

Abstract: The present invention provides an avian recombinant herpesvirus modified by the presence of the cDNA encoding the VP2 of the Delaware Variant E strain of IBDV, a subtype of IBDV serotype 1 strains. The present invention further provides an avian recombinant herpesvirus comprised of the VP2 gene, of which the backbone virus is a Marek's disease vaccine strain, such as herpesvirus of turkeys. A poultry vaccine including the avian herpes recombinant virus described in the present invention can induce in chickens protective immunity against a variety of different subtypes of IBDV.

Abstract: An avian infectious recombinant herpesvirus is prepared by inserting a foreign gene, in particular a heterologous antigen gene, into an insertion site in an untranslated genetic region in the genome. A chicken vaccine comprising such a recombinant virus is also provided.

Abstract: The present invention provides a recombinant herpesvirus of turkeys modified by the presence of cDNA encoding the F protein of Newcastle disease virus under the control of a promoter. The poultry vaccine consisting of the recombinant herpesvirus of turkeys of the present invention can induce in chickens protective immunity against Newcastle disease virus.

Abstract: The present invention provides an avian recombinant herpesvirus modified by the presence of the cDNA encoding the VP2 of the Delaware Variant E strain of IBDV, a subtype of IBDV serotype I strains. The present invention further provides an avian recombinant herpesvirus comprised of the VP2 gene, of which the backbone virus is a Marek's disease vaccine strain, such as herpesvirus of turkeys. A poultry vaccine including the avian herpes recombinant virus described in the present invention can induce in chickens protective immunity against a variety of different subtypes of IBDV.

Abstract: A DNA coding for a fusion protein comprising a polypeptide having the antigenicity of Mycoplasma gallisepticum and a polypeptide derived from Herpesvirus outer membrane protein, in which the polypeptide derived from the outer membrane protein has been ligated with the polypeptide having the antigenicity of Mycoplasma gallisepticum at the N terminus thereof, is prepared. The DNA is inserted into a region non-essential to growth of Avipox virus and the resulting recombinant Avipox virus is provided as a more potent recombinant virus as an anti-Mycoplasma vaccine.

Abstract: A polypeptide exhibiting the antigenicity of Mycoplasma gallisepticum, a fused polypeptide comprising the above polypeptide and, connected to the N-terminus thereof, a signal membrane anchor of a type II outer-membrane polypeptide of a virus that infects birds, or a polypeptide capable of reacting with a mycoplasma-immune serum or a mycoplasma-infected serum and exhibiting a substantially pure antigenecity, respectively having amino acid sequences of about 32 kDa, about 40 kDa, or about 70 kDa. The expression with a recombinant virus of a polypeptide modified to such an extent as to exhibit an antigenicity equivalent to that of any of the above polypeptides. The use of a recombinant virus as a live vaccine.